CSIMarket
 


Dr Reddy s Laboratories Limited  (RDY)
Other Ticker:  
 

Cumulative Dr Reddy S Laboratories Limited's Working Capital Ratio for Trailing Twelve Months Period

RDY's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

RDY Working Capital Ratio for Trailing Twelve Months Period

(Mar 31 2023)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Mar 31 2021)
IV. Quarter
Y / Y Current Liabilities Growth -8.42 % -8.42 % -8.42 % -8.42 % 18.01 %
Y / Y Current Assets Growth 24.22 % 24.22 % 24.22 % 24.22 % 17.24 %
Working Capital Ratio for Trailing Twelve Months Period 2.41 2.24 2.08 1.93 1.78
Total Ranking # 1699 # # # 2764 # 3118
Seq. Current Liabilities Growth 0 % 0 % 0 % -8.42 % 0 %
Seq. Current Assets Growth 0 % 0 % 0 % 24.22 % 0 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Mar 31 2023
On the trailing twelve months basis Dr Reddy S Laboratories Limited Current Assets average grew by 24.22% in IV. Quarter year on year, while Current Liabilities remained unchanged to $ 1,044 millions, this led to increase in in Dr Reddy S Laboratories Limited's Working Capital Ratio for Trailing Twelve Months Period to 2.41, Working Capital Ratio for Trailing Twelve Months Period remained below Dr Reddy s Laboratories Limited average.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 393 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Dr Reddy S Laboratories Limited. While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about RDY
Working Capital Ratio RDY in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 394
Sector # 736
S&P 500 # 1693


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
2.41 1.89 1.78
(Mar 31 2023)   (Mar 31 2022)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Hcw Biologics Inc   6.62 
Roivant Sciences Ltd   6.60 
Frequency Therapeutics Inc   6.58 
Calcimedica Inc   6.52 
Inflarx N v   6.50 
Blueprint Medicines Corporation  6.45 
Entasis Therapeutics Holdings Inc   6.42 
Tango Therapeutics Inc   6.39 
Biodexa Pharmaceuticals Plc  6.39 
Sarepta Therapeutics Inc   6.39 
Aveo Pharmaceuticals Inc   6.38 
Xilio Therapeutics inc   6.36 
Annovis Bio inc   6.33 
Revance Therapeutics Inc   6.33 
Dynavax Technologies Corporation  6.26 
Zymeworks Inc   6.25 
Lipella Pharmaceuticals Inc   6.24 
Arcturus Therapeutics Holdings Inc   6.24 
Catalyst Biosciences Inc   6.21 
Sinovac Biotech Ltd  6.18 
Gt Biopharma Inc   6.18 
Alterity Therapeutics Limited  6.17 
Applied Molecular Transport Inc   6.15 
Galmed Pharmaceuticals Ltd   6.13 
Therapeuticsmd Inc   6.11 
Nucana Plc  6.11 
Vyne Therapeutics Inc   6.06 
Biomea Fusion Inc   6.05 
Adc Therapeutics Sa  6.03 
Ocular Therapeutix Inc   6.02 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com